Clinical trials: Pulmonary Fibrosis, open to volunteers
Cystic Fibrosis, CFTR Gene Mutation
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor…
- Trial name
- LunairCF (NCT06747858)
- Testing
- ARCT-032
- Where
- 13 sites in United States
- Volunteers
- 33 people
- Sponsor
- Arcturus Therapeutics, Inc.
Interstitial Fibrosis, Kidney Transplant; Complications
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard…
- Conditions
- Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection
- Trial name
- NCT05285878
- Testing
- Fingolimod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a type of scarring (fibrotic) lung disease. Reduced exercise capacity is a key symptom experienced by patients.
- Trial name
- BEET-IPF (NCT06488638)
- Testing
- nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Interstitial Lung Disease, Pulmonary Fibrosis
P4O2 ILD Extension
The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs).
- Conditions
- Interstitial Lung Disease, Pulmonary Fibrosis, Interstitial Lung Fibrosis, IPF
- Trial name
- P4O2-ILD (NCT06644144)
- Testing
- No Interventions
- Where
- Netherlands
- Volunteers
- 450 people
- Sponsor
- Amsterdam UMC, location VUmc
Cystic Fibrosis
A Usability Validation of the MuCopilot Mobile Application, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis
The study aims to assess the usability and safety of use of MuCopilot, a smartphone application that measures objective data on lung function, global exercise capacity and patient reported outcomes of patients with Cystic…
- Trial name
- MuControl-Sum (NCT06132048)
- Testing
- MuCopilot mobile application
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Ad scientiam
Cystic Fibrosis (CF), Chronic Kidney Disease(CKD)
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
The purpose of this study is to find out what causes kidney disease in people with CF. The investigators will study biomarkers in the blood and urine that can either predict who is at risk or detect kidney damage early before it…
- Conditions
- Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Acute Kidney Injury
- Trial name
- NCT06595420
- Where
- 3 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Pulmonary Fibrosis, Interstitial Lung Disease (ILD)
This is a Trial Designed to Evaluate the Combination of Nerandomilast With Mycophenolate Across a Wide Variety of Pulmonary Fibrosis Subtypes, With the Aim of Providing Clinicians With Assurance That This is an Appropriate Therapeutic Combination.
This is a trial designed to evaluate the combination of nerandomilast with mycophenolate across a wide variety of pulmonary fibrosis subtypes, with the aim of providing clinicians with assurance that this is an appropriate…
- Trial name
- NERAM-PF (NCT07570888)
- Testing
- Nerandomilast 18 mg - adult formulation
- Volunteers
- 120 people
- Sponsor
- University of British Columbia
Pulmonary Fibrosis, Lung Fibrosis
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
- Conditions
- Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP
- Trial name
- FAPIPET (NCT06189820)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Erasme University Hospital
Cystic Fibrosis
Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA…
- Trial name
- NCT07283770
- Testing
- VX-581, D-IVA, TEZ
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis in Children, Cystic Fibrosis
Sinus Disease in Young Children With Cystic Fibrosis
This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young…
- Conditions
- Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder
- Trial name
- NCT06191640
- Testing
- Ivacaftor or elexacaftor/tezacaftor/ivacaftor
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of California, Los Angeles
Cough, Asthma
Validation of the C-mo System - Cough Monitoring
The goal of this clinical study is to validate C-mo System's ability to automatically detect and characterise cough, in patients over 2 years old with cough as a key or refractory symptom.
- Conditions
- Cough, Asthma, Chronic Obstructive Pulmonary Disease, Gastro Esophageal Reflux
- Trial name
- C-mo_01 (NCT05989698)
- Testing
- C-mo System
- Where
- 8 sites in Portugal
- Volunteers
- 300 people
- Sponsor
- Cough Monitoring Medical Solutions
Idiopathic Pulmonary Fibrosis
A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study. It Aims aims to evaluate the efficacy and safety of different doses of SYH2059 tablets compared with placebo in adult patients with IPF, observe…
- Trial name
- NCT07600021
- Testing
- SYH2059 Tablets
- Volunteers
- 156 people
- Sponsor
- InnovStone Therapeutics Limited
Cystic Fibrosis
Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)
Cystic fibrosis (CF) is a multisystem autosomal recessive inherited disease affecting approximately 75,000 individuals in USA. The sweat chloride (Cl) test remains the gold standard for diagnosis of CF but still has a number of…
- Trial name
- NCT05998629
- Testing
- a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels, Standard of Care laboratory procedure for measurement of sweat
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis
This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.
- Conditions
- Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Trial name
- UPWARD (NCT07722507)
- Testing
- Antifibrotic therapy
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Pulmonary Fibrosis, Interstitial Lung Disease
Retrospective Validation of AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This retrospective observational study evaluates the diagnostic performance of AccuPulmo CT Portal, an artificial intelligence-assisted medical imaging software, for detecting pulmonary fibrosis on pre-existing chest computed…
- Trial name
- ACCUPULMO-FIBR (NCT07761377)
- Testing
- AccuPulmo CT Portal
- Where
- Taiwan
- Volunteers
- 900 people
- Sponsor
- Taichung Veterans General Hospital
Cystic Fibrosis
Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial
Cystic fibrosis is an autosomal recessive inherited disease linked to various mutations in the gene coding for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, with respiratory and digestive disorders…
- Trial name
- DIAPASOM (NCT06457451)
- Testing
- DIAPASOM program
- Where
- 4 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Tours
Idiopathic Granulomatous Mastitis, Granulomatous Mastitis
GRAnulomatous MAstitis REGistry Study
Idiopathic granulomatous mastitis (IGM) is a rare benign inflammatory breast condition with unknown cause, affecting approximately 2.4 per 100,000 women aged 20-40 years.
- Trial name
- GRAMAREG (NCT07422870)
- Where
- 2 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- European Breast Cancer Research Association of Surgical Trialists
Cystic Fibrosis
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.
- Trial name
- SAAVe (NCT06526923)
- Testing
- SP-101 and doxorubicin Cohort 1, SP-101 and doxorubicin Cohort 2
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Spirovant Sciences, Inc.
Scleroderma, Systemic, Fibrosis; Skin
Western Sweden Systemic Sclerosis Project
The main aim of the project is to identify key-factors involved in the development and progression of Systemic Sclerosis (SSc), a chronic invalidating rheumatic disease characterized by high mortality and insufficient treatment…
- Conditions
- Scleroderma, Systemic, Fibrosis; Skin, Fibrosis Lung, Interstitial Lung Disease Due to Systemic Disease
- Trial name
- WESST (NCT07345052)
- Testing
- No Intervention: Observational Cohort
- Where
- Sweden
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis
European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of…
- Conditions
- Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis, Pulmonary Eosinophilia, Pulmonary Fibrosis
- Trial name
- chILD-EU (NCT02852928)
- Where
- 3 sites in Germany, Turkey (Türkiye) and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Matthias Griese